Kidney Disease Management: Treatment Options by Stage and Etiology

Chronic kidney disease (CKD) affects 15% of US adults. While most CKD is not "curable," progression can be slowed, complications managed, and quality of life preserved through stage-appropriate interventions.

CKD Staging (KDIGO)

Conservative Management (All Stages)

Blood Pressure Control

  • Target <130/80 (KDIGO/ACC/AHA)
  • ACEi/ARB first-line: Renoprotective (reduce intraglomerular pressure, proteinuria)
  • Add thiazide (G1-3), loop diuretic (G4-5), CCB, MRA as needed

Glycemic Control (Diabetic Kidney Disease)

  • SGLT2 inhibitors: Empagliflozin, dapagliflozin, canagliflozin — renal & CV benefit independent of glucose
  • GLP-1 RAs: Semaglutide, dulaglutide — renal benefit
  • A1c target individualized (generally <7%, higher if frail/hypoglycemia risk)

Lipid Management

  • Statin ± ezetimibe for CVD prevention (CKD = CVD risk equivalent)

Dietary Modifications

  • Sodium <2.3 g/day (5 g salt)
  • Protein 0.8 g/kg/day (G3-5, non-dialysis); avoid high protein
  • Potassium restriction if hyperkalemic (G4-5)
  • Phosphate restriction if hyperphosphatemic (G4-5)
  • Plant-dominant diet may slow progression

Anemia Management

  • Iron repletion (IV preferred in CKD)
  • ESAs (epoetin, darbepoetin) if Hb <10 g/dL; target 10-11 g/dL
  • HIF-PH inhibitors (roxadustat, vadadustat) — emerging oral alternative

Mineral and Bone Disorder (CKD-MBD)

  • Phosphate binders (calcium-based, sevelamer, lanthanum, sucroferric oxyhydroxide)
  • Vitamin D analogs (calcitriol, paricalcitol) for secondary hyperparathyroidism
  • Calcimimetics (cinacalcet) for refractory SHPT

Kidney Replacement Therapy (KRT) — Stage G5

Hemodialysis

  • In-center (3×/week) or home (more frequent, better outcomes)
  • Vascular access: AVF > AVG > catheter

Peritoneal Dialysis

  • Continuous ambulatory (CAPD) or automated (APD)
  • Preserves residual function; more lifestyle flexibility

Kidney Transplant

  • Best survival and quality of life
  • Living donor preferred (preemptive ideal)
  • Deceased donor waitlist: 3-5+ years

Conservative / Palliative Care

  • Symptom management without dialysis
  • Appropriate for frail, elderly, multi-morbid patients
  • Advance care planning essential

Acute Kidney Injury (AKI) — Potentially Reversible

  • Prerenal (volume), intrinsic (ATN, GN, AIN), postrenal (obstruction)
  • Early recognition, volume optimization, nephrotoxin avoidance, RRT if indicated
  • Recovery common but increases long-term CKD risk

Multidisciplinary Care

  • Nephrologist, dietitian, pharmacist, social worker, vascular access coordinator
  • Patient education: CKD stage, trajectory, options, advance directives
  • Early referral (G3b) improves outcomes

CKD management is proactive, not reactive. Slowing progression preserves options and years of life.

Kidney Disease - Related Articles

Health Sciences © https://www.222health.com

StageeGFR (mL/min/1.73m²)Focus
G1≥90Normal/high; monitor if kidney damage present
G260-89Mildly decreased; risk factor control
G3a45-59Mild-moderate; complication screening
G3b30-44Moderate-severe; nephrology referral
G415-29Severe; prepare for KRT
G5<15Kidney failure; KRT initiation